Traders Sell Eli Lilly and (LLY) on Strength (LLY)

Investors sold shares of Eli Lilly and Co (NYSE:LLY) on strength during trading hours on Friday. $33.12 million flowed into the stock on the tick-up and $84.38 million flowed out of the stock on the tick-down, for a money net flow of $51.26 million out of the stock. Of all equities tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $0.59 for the day and closed at $86.98

LLY has been the subject of several recent research reports. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a report on Thursday, October 26th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a report on Thursday, October 26th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a report on Friday, October 13th. Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Finally, Cowen reaffirmed a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a report on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and an average target price of $92.14.

The stock has a market capitalization of $95,773.24, a P/E ratio of 21.27, a PEG ratio of 1.63 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter last year, the company earned $0.88 EPS. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. research analysts forecast that Eli Lilly and Co will post 4.22 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.59%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders sold a total of 251,088 shares of company stock worth $22,041,236 in the last three months. 0.20% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in LLY. Janus Henderson Group PLC boosted its stake in Eli Lilly and by 7,093.5% during the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after purchasing an additional 9,223,251 shares during the last quarter. Dodge & Cox boosted its stake in Eli Lilly and by 22,094.9% during the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after purchasing an additional 5,964,955 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Eli Lilly and by 91.1% during the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after purchasing an additional 2,714,505 shares during the last quarter. Vanguard Group Inc. boosted its stake in Eli Lilly and by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after purchasing an additional 1,610,885 shares during the last quarter. Finally, AJO LP boosted its position in shares of Eli Lilly and by 1,364.2% during the 2nd quarter. AJO LP now owns 1,700,302 shares of the company’s stock valued at $139,935,000 after acquiring an additional 1,584,176 shares during the last quarter. 76.31% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://weekherald.com/2018/01/14/traders-sell-eli-lilly-and-lly-on-strength-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply